Log in
Enquire now
‌

US Patent 8921528 Bispecific fusion antibodies with enhanced serum half-life

Patent 8921528 was granted and assigned to Domantis Limited on December, 2014 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
‌
Domantis Limited
0
Date Filed
May 31, 2005
0
Date of Patent
December 30, 2014
0
Patent Application Number
11628149
0
Patent Citations Received
‌
US Patent 11859001 IL12RB1-Binding molecules and methods of use
0
‌
US Patent 11873349 Compositions and methods related to IL27 receptor binding
0
‌
US Patent 12006361 Albumin binding domain fusion proteins
0
‌
US Patent 12018085 Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
0
‌
US Patent 12012457 IL23R binding molecules and methods of use
0
‌
US Patent 12077594 IL2RG binding molecules and methods of use
0
‌
US Patent 12134635 Interleukin 18 (IL-18) variants and fusion proteins comprising same
0
‌
US Patent 12122839 IFNGR binding synthetic cytokines and methods of use
0
‌
US Patent 12103922 Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
0
Patent Inventor Names
Lucy J. Holt
0
Ian M. Tomlinson
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
8921528
0
Patent Primary Examiner
‌
Phuong Huynh
0

Find more entities like US Patent 8921528 Bispecific fusion antibodies with enhanced serum half-life

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.